These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2850327)

  • 41. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma thrombin neutralization assay: pharmacokinetic applications.
    Iorio A; Alatri A; Mazzolai L; Agnelli G
    Semin Thromb Hemost; 1994; 20(3):266-73. PubMed ID: 7824961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
    Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human pharmacokinetics of low molecular weight heparins.
    Cornelli U; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 49. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-IIa and anti-Xa plasma activities after subcutaneous low-dose application of low-molecular-weight heparins to rabbits.
    Harbauer G; Kettenring P
    Haemostasis; 1988; 18 Suppl 3():64-8. PubMed ID: 2840376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B; Faruel-Bille V; Pierrejean D; Gabaig AM
    Nouv Rev Fr Hematol (1978); 1991; 33(4):287-91. PubMed ID: 1664095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
    Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).
    Andrassy K; Mörike K; Koderisch J; Weber E
    Thromb Res; 1988 Mar; 49(6):601-11. PubMed ID: 3164530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
    Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
    Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.
    Omri A; Delaloye JF; Andersen H; Bachmann F
    Thromb Haemost; 1989 Feb; 61(1):55-6. PubMed ID: 2546279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Low molecular weight heparin fractions. Comparative preclinical study of various parameters].
    Fareed J
    J Mal Vasc; 1987; 12 Suppl B():59-63. PubMed ID: 2834492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
    Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M
    Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating activities during constant infusion of heparin or a low molecular weight derivative (enoxaparine): failure to demonstrate any circadian variations.
    Toulon P; Vitoux JF; Leroy C; Lecomte T; Roncato M; Motobashi Y; Aiach M; Fiessinger JN
    Thromb Haemost; 1987 Dec; 58(4):1068-72. PubMed ID: 2832964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.